MedElevator
Войти в исследования Veterinary research communications · 2026
Multivalent fowl Adenovirus-Newcastle disease vaccine: comprehensive evaluation in SPF and commercial broiler breeders.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yahia Nahed, Abdelhalim Ahmed, Mahmoud Sara Hussein, Bazid Abdelhamid, Kumar Ravi, Aljassas Hussein, Alhnout Maryam, Alhassan Dana, Hussien Hussien Ali, Eid Samah, Khalil Ahmed Aly
Аннотация
BACKGROUND: Inclusion body hepatitis (IBH) and Newcastle disease (ND) impose substantial economic burdens on global poultry production, with combined annual losses exceeding $3 billion worldwide. Current vaccination strategies requiring separate immunizations increase handling stress and operational costs.
OBJECTIVE: To evaluate immunogenicity, cross-neutralization patterns, protective efficacy against virulent challenge, maternal antibody transfer, and commercial field performance of a novel multivalent inactivated vaccine containing fowl adenovirus (FAdV) serotypes 2, 8a, 8b, and 11 combined with Newcastle disease virus (NDV).
METHODS: Two randomized, blinded, placebo-controlled trials were conducted: SPF trial (n = 200, Egypt) and commercial field trial (n = 120,000, Saudi Arabia). The multivalent vaccine contained inactivated FAdV serotypes 2, 8a, 8b, and 11 plus NDV strains, administered at 10 and 16 weeks of age with 24-week monitoring.
RESULTS: Vaccination induced robust antibody responses with FAdV ELISA geometric mean titers (GMT) reaching 22,847 (95% CI: 18,245 - 28,589) at weeks 4-6 post-primary vaccination, with peak anamnestic response of 28,945 (95% CI: 23,186 - 36,115) at week 8 following booster (p < 0.001) and NDV hemagglutination inhibition titers of 9.8 log₂ (95% CI: 8.4-11.4) (p < 0.001). Challenge studies demonstrated 96.7% protection against FAdV-2 (species D) (29/30 vaccinated vs. 6/30 controls; Fisher's exact p < 0.0001) and 100% protection against NDV (30/30 vs. 0/30). Maternal antibody transfer efficiency was 68.6% for IBH and 81.7% for NDV, with half-lives of 4.2 and 4.8 days respectively, providing 24-28 days and 21-24 days protection in progeny. Commercial field trial (120,000 birds) demonstrated 94.2% reduction in IBH mortality with 3.47:1 return on investment.
CONCLUSIONS: The multivalent IBH-NDV vaccine provides comprehensive immunological protection and consistent field efficacy. Although the cross-neutralization assay included representative serotypes, broader testing across additional field isolates is warranted to further define cross-protective breadth. Cross-neutralization analysis confirms the necessity of multivalent formulations due to type-specific immunity patterns, supporting implementation for integrated disease control in commercial broiler operations. This study provides a detailed evaluation of a quadrivalent FAdV-NDV inactivated vaccine demonstrating efficient maternal antibody transfer in broiler breeders.
OBJECTIVE: To evaluate immunogenicity, cross-neutralization patterns, protective efficacy against virulent challenge, maternal antibody transfer, and commercial field performance of a novel multivalent inactivated vaccine containing fowl adenovirus (FAdV) serotypes 2, 8a, 8b, and 11 combined with Newcastle disease virus (NDV).
METHODS: Two randomized, blinded, placebo-controlled trials were conducted: SPF trial (n = 200, Egypt) and commercial field trial (n = 120,000, Saudi Arabia). The multivalent vaccine contained inactivated FAdV serotypes 2, 8a, 8b, and 11 plus NDV strains, administered at 10 and 16 weeks of age with 24-week monitoring.
RESULTS: Vaccination induced robust antibody responses with FAdV ELISA geometric mean titers (GMT) reaching 22,847 (95% CI: 18,245 - 28,589) at weeks 4-6 post-primary vaccination, with peak anamnestic response of 28,945 (95% CI: 23,186 - 36,115) at week 8 following booster (p < 0.001) and NDV hemagglutination inhibition titers of 9.8 log₂ (95% CI: 8.4-11.4) (p < 0.001). Challenge studies demonstrated 96.7% protection against FAdV-2 (species D) (29/30 vaccinated vs. 6/30 controls; Fisher's exact p < 0.0001) and 100% protection against NDV (30/30 vs. 0/30). Maternal antibody transfer efficiency was 68.6% for IBH and 81.7% for NDV, with half-lives of 4.2 and 4.8 days respectively, providing 24-28 days and 21-24 days protection in progeny. Commercial field trial (120,000 birds) demonstrated 94.2% reduction in IBH mortality with 3.47:1 return on investment.
CONCLUSIONS: The multivalent IBH-NDV vaccine provides comprehensive immunological protection and consistent field efficacy. Although the cross-neutralization assay included representative serotypes, broader testing across additional field isolates is warranted to further define cross-protective breadth. Cross-neutralization analysis confirms the necessity of multivalent formulations due to type-specific immunity patterns, supporting implementation for integrated disease control in commercial broiler operations. This study provides a detailed evaluation of a quadrivalent FAdV-NDV inactivated vaccine demonstrating efficient maternal antibody transfer in broiler breeders.